Table of Contents

2019-2024 Global Acute Migraine Drugs Consumption Market Report

1 Scope of the Report

• 1.1 Market Introduction
• 1.2 Research Objectives
• 1.3 Years Considered
• 1.4 Market Research Methodology
• 1.5 Economic Indicators
• 1.6 Currency Considered

2 Executive Summary

• 2.1 World Market Overview
  • 2.1.1 Global Acute Migraine Drugs Consumption 2014-2024
  • 2.1.2 Acute Migraine Drugs Consumption CAGR by Region
• 2.2 Acute Migraine Drugs Segment by Type
  • 2.2.1 Nonsteroidal Anti-Inflammatory Drugs
  • 2.2.2 Triptans
  • 2.2.3 Dihydroergotamine
  • 2.2.4 Nonspecific Migraine Medications
  • 2.2.5 Analgesics
• 2.3 Acute Migraine Drugs Consumption by Type
  • 2.3.1 Global Acute Migraine Drugs Consumption Market Share by Type (2014-2019)
  • 2.3.2 Global Acute Migraine Drugs Revenue and Market Share by Type (2014-2019)
  • 2.3.3 Global Acute Migraine Drugs Sale Price by Type (2014-2019)
• 2.4 Acute Migraine Drugs Segment by Application
  • 2.4.1 Hospital Pharmacies
  • 2.4.2 Drug Stores
  • 2.4.3 Retail Pharmacies
  • 2.4.4 Online Pharmacies
• 2.5 Acute Migraine Drugs Consumption by Application
  • 2.5.1 Global Acute Migraine Drugs Consumption Market Share by Application (2014-2019)
  • 2.5.2 Global Acute Migraine Drugs Value and Market Share by Application (2014-2019)
  • 2.5.3 Global Acute Migraine Drugs Sale Price by Application (2014-2019)

3 Global Acute Migraine Drugs by Manufacturers

• 3.1 Global Acute Migraine Drugs Sales Market Share by Manufacturers
  • 3.1.1 Global Acute Migraine Drugs Sales by Manufacturers (2017-2019)
  • 3.1.2 Global Acute Migraine Drugs Sales Market Share by Manufacturers (2017-2019)
• 3.2 Global Acute Migraine Drugs Revenue Market Share by Manufacturers
  • 3.2.1 Global Acute Migraine Drugs Revenue by Manufacturers (2017-2019)
  • 3.2.2 Global Acute Migraine Drugs Revenue Market Share by Manufacturers (2017-2019)
• 3.3 Global Acute Migraine Drugs Sale Price by Manufacturers
• 3.4 Global Acute Migraine Drugs Manufacturing Base Distribution, Sales Area, Product Types by Manufacturers
  • 3.4.1 Global Acute Migraine Drugs Manufacturing Base Distribution and Sales Area by Manufacturers
  • 3.4.2 Players Acute Migraine Drugs Products Offered
• 3.5 Market Concentration Rate Analysis
  • 3.5.1 Competition Landscape Analysis
  • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2017-2019)
• 3.6 New Products and Potential Entrants
• 3.7 Mergers & Acquisitions, Expansion

4 Acute Migraine Drugs by Regions

• 4.1 Acute Migraine Drugs by Regions
  • 4.1.1 Global Acute Migraine Drugs Consumption by Regions
  • 4.1.2 Global Acute Migraine Drugs Value by Regions
• 4.2 Americas Acute Migraine Drugs Consumption Growth
• 4.3 APAC Acute Migraine Drugs Consumption Growth
• 4.4 Europe Acute Migraine Drugs Consumption Growth
• 4.5 Middle East & Africa Acute Migraine Drugs Consumption Growth

5 Americas

• 5.1 Americas Acute Migraine Drugs Consumption by Countries
  • 5.1.1 Americas Acute Migraine Drugs Consumption by Countries (2014-2019)
  • 5.1.2 Americas Acute Migraine Drugs Value by Countries (2014-2019)
• 5.2 Americas Acute Migraine Drugs Consumption by Type
• 5.3 Americas Acute Migraine Drugs Consumption by Application
• 5.4 United States
• 5.5 Canada
• 5.6 Mexico
• 5.7 Key Economic Indicators of Few Americas Countries

6 APAC

• 6.1 APAC Acute Migraine Drugs Consumption by Countries
  • 6.1.1 APAC Acute Migraine Drugs Consumption by Countries (2014-2019)
  • 6.1.2 APAC Acute Migraine Drugs Value by Countries (2014-2019)
• 6.2 APAC Acute Migraine Drugs Consumption by Type
• 6.3 APAC Acute Migraine Drugs Consumption by Application
• 6.4 China
• 6.5 Japan
• 6.6 Korea
• 6.7 Southeast Asia
• 6.8 India
• 6.9 Australia
• 6.10 Key Economic Indicators of Few APAC Countries

7 Europe

• 7.1 Europe Acute Migraine Drugs by Countries
  • 7.1.1 Europe Acute Migraine Drugs Consumption by Countries (2014-2019)
  • 7.1.2 Europe Acute Migraine Drugs Value by Countries (2014-2019)
• 7.2 Europe Acute Migraine Drugs Consumption by Type
• 7.3 Europe Acute Migraine Drugs Consumption by Application
• 7.4 Germany
• 7.5 France
• 7.6 UK
• 7.7 Italy
• 7.8 Russia
• 7.9 Spain
• 7.10 Key Economic Indicators of Few Europe Countries

8 Middle East & Africa

• 8.1 Middle East & Africa Acute Migraine Drugs by Countries
  • 8.1.1 Middle East & Africa Acute Migraine Drugs Consumption by Countries (2014-2019)
  • 8.1.2 Middle East & Africa Acute Migraine Drugs Value by Countries (2014-2019)
• 8.2 Middle East & Africa Acute Migraine Drugs Consumption by Type
• 8.3 Middle East & Africa Acute Migraine Drugs Consumption by Application
• 8.4 Egypt
• 8.5 South Africa
• 8.6 Israel
• 8.7 Turkey
• 8.8 GCC Countries

9 Market Drivers, Challenges and Trends

• 9.1 Market Drivers and Impact
  • 9.1.1 Growing Demand from Key Regions
  • 9.1.2 Growing Demand from Key Applications and Potential Industries
• 9.2 Market Challenges and Impact
• 9.3 Market Trends

10 Marketing, Distributors and Customer

• 10.1 Sales Channel
  • 10.1.1 Direct Channels
  • 10.1.2 Indirect Channels
• 10.2 Acute Migraine Drugs Distributors
• 10.3 Acute Migraine Drugs Customer

11 Global Acute Migraine Drugs Market Forecast

• 11.1 Global Acute Migraine Drugs Consumption Forecast (2019-2024)
• 11.2 Global Acute Migraine Drugs Forecast by Regions
  • 11.2.1 Global Acute Migraine Drugs Forecast by Regions (2019-2024)
  • 11.2.2 Global Acute Migraine Drugs Value Forecast by Regions (2019-2024)
  • 11.2.3 Americas Consumption Forecast
  • 11.2.4 APAC Consumption Forecast
  • 11.2.5 Europe Consumption Forecast
  • 11.2.6 Middle East & Africa Consumption Forecast
• 11.3 Americas Forecast by Countries
  • 11.3.1 United States Market Forecast
  • 11.3.2 Canada Market Forecast
  • 11.3.3 Mexico Market Forecast
  • 11.3.4 Brazil Market Forecast
• 11.4 APAC Forecast by Countries
  • 11.4.1 China Market Forecast
  • 11.4.2 Japan Market Forecast
  • 11.4.3 Korea Market Forecast
  • 11.4.4 Southeast Asia Market Forecast
  • 11.4.5 India Market Forecast
  • 11.4.6 Australia Market Forecast
• 11.5 Europe Forecast by Countries
  • 11.5.1 Germany Market Forecast
  • 11.5.2 France Market Forecast
  • 11.5.3 UK Market Forecast
  • 11.5.4 Italy Market Forecast
  • 11.5.5 Russia Market Forecast
  • 11.5.6 Spain Market Forecast
• 11.6 Middle East & Africa Forecast by Countries
  • 11.6.1 Egypt Market Forecast
  • 11.6.2 South Africa Market Forecast
  • 11.6.3 Israel Market Forecast
  • 11.6.4 Turkey Market Forecast
  • 11.6.5 GCC Countries Market Forecast
• 11.7 Global Acute Migraine Drugs Forecast by Type
• 11.8 Global Acute Migraine Drugs Forecast by Application

12 Key Players Analysis

• 12.1 Amgen
  • 12.1.1 Company Details
  • 12.1.2 Acute Migraine Drugs Product Offered
  • 12.1.3 Amgen Acute Migraine Drugs Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.1.4 Main Business Overview
  • 12.1.5 Amgen News
• 12.2 Pfizer
  • 12.2.1 Company Details
  • 12.2.2 Acute Migraine Drugs Product Offered
  • 12.2.3 Pfizer Acute Migraine Drugs Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.2.4 Main Business Overview
  • 12.2.5 Pfizer News
• 12.3 Novartis
  • 12.3.1 Company Details
  • 12.3.2 Acute Migraine Drugs Product Offered
  • 12.3.3 Novartis Acute Migraine Drugs Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.3.4 Main Business Overview
  • 12.3.5 Novartis News
• 12.4 Eli Lily
  • 12.4.1 Company Details
  • 12.4.2 Acute Migraine Drugs Product Offered
  • 12.4.3 Eli Lily Acute Migraine Drugs Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.4.4 Main Business Overview
  • 12.4.5 Eli Lily News
• 12.5 AstraZeneca
  • 12.5.1 Company Details
  • 12.5.2 Acute Migraine Drugs Product Offered
  • 12.5.3 AstraZeneca Acute Migraine Drugs Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.5.4 Main Business Overview
  • 12.5.5 AstraZeneca News
• 12.6 Teva Pharmaceutical
  • 12.6.1 Company Details
  • 12.6.2 Acute Migraine Drugs Product Offered
  • 12.6.3 Teva Pharmaceutical Acute Migraine Drugs Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.6.4 Main Business Overview
  • 12.6.5 Teva Pharmaceutical News
• 12.7 Allergan
  • 12.7.1 Company Details
  • 12.7.2 Acute Migraine Drugs Product Offered
  • 12.7.3 Allergan Acute Migraine Drugs Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.7.4 Main Business Overview
  • 12.7.5 Allergan News
• 12.8 Abbott
  • 12.8.1 Company Details
  • 12.8.2 Acute Migraine Drugs Product Offered
  • 12.8.3 Abbott Acute Migraine Drugs Sales, Revenue, Price and Gross Margin (2017-2019)
  • 12.8.4 Main Business Overview
  • 12.8.5 Abbott News

13 Research Findings and Conclusion

A migraine is an episodic and unpredictable headache disorder that presents with disabling attack. Acute medications fall into general classes of medicines including analgesics, ergotamines and triptans.

According to this study, over the next five years the Acute Migraine Drugs market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Acute Migraine Drugs business, shared in Chapter 3.

This report presents a comprehensive overview, market shares, and growth opportunities of Acute Migraine Drugs market by product type, application, key manufacturers and key regions and countries.

This study considers the Acute Migraine Drugs value and volume generated from the sales of the following segments:

Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3; and forecast to 2024 in section 11.7.
Nonsteroidal Anti-Inflammatory Drugs
Triptans
Dihydroergotamine
Nonspecific Migraine Medications
Analgesics
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4; and forecast to 2024 in section 11.8.
Hospital Pharmacies
Drug Stores
Retail Pharmacies
Online Pharmacies

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Amgen
Pfizer
Novartis
Eli Lily
AstraZeneca
Teva Pharmaceutical
Allergan
Abbott

In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

Research objectives
To study and analyze the global Acute Migraine Drugs consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Acute Migraine Drugs market by identifying its various subsegments.
Focuses on the key global Acute Migraine Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Acute Migraine Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Acute Migraine Drugs submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.